Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes

Kalyani D Panse, Leanne E Felkin, Marina M Lopez-Olaneta, Jesus M Gomez-Salinero, Maria Villalba, Lucia Munoz, Kazuto Nakamura, Masayuki Shimano, Kenneth Walsh, Paul JR Barton, Nadia Alicia Rosenthal, Enrique Lara-Pezzi

Research output: Contribution to journalArticleResearchpeer-review

37 Citations (Scopus)

Abstract

Follistatins are extracellular inhibitors of the TGF-beta family ligands including activin A, myostatin and bone morphogenetic proteins. Follistatin-like 3 (FSTL3) is a potent inhibitor of activin signalling and antagonises the cardioprotective role of activin A in the heart. FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown. Here, we show that the production of FSTL3 by cardiomyocytes contributes to the paracrine activation of cardiac fibroblasts, inducing changes in cell adhesion, promoting proliferation and increasing collagen production. We found that FSTL3 is necessary for this response and for the induction of cardiac fibrosis. However, full activation requires additional factors, and we identify connective tissue growth factor as a FSTL3 binding partner in this process. Together, our data unveil a novel mechanism of paracrine communication between cardiomyocytes and fibroblasts that may provide potential as a therapeutic target in heart remodelling.
Original languageEnglish
Pages (from-to)814 - 826
Number of pages13
JournalJournal of Cardiovascular Translational Research
Volume5
Issue number6
DOIs
Publication statusPublished - 2012

Cite this